FAST NEWS: Antengene Acquires Full Interest in Anti-Tumor Cancer Drug
The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) said on Wednesday it has agreed to acquire the remaining interest it doesn’t already hold in the anti-tumor drug ATG-037 from Calithera Biosciences (CALA.US), giving…
RELATED ARTICLES
-
FAST NEWS: Antengene appoints Hansoh to commercialize myeloma drug
6996.HK
-
FAST NEWS: Antengene’s loss widens on lower forex income, rising R&D costs
6996.HK
-
HBM gets health boost from drug licensing deals
2142.HK
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG
Discover hidden China stock gems in our weekly newsletter